NO20064146L - En farmasoytisk sammensetning - Google Patents
En farmasoytisk sammensetningInfo
- Publication number
- NO20064146L NO20064146L NO20064146A NO20064146A NO20064146L NO 20064146 L NO20064146 L NO 20064146L NO 20064146 A NO20064146 A NO 20064146A NO 20064146 A NO20064146 A NO 20064146A NO 20064146 L NO20064146 L NO 20064146L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- extraction process
- present
- gelatin
- collagen source
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
Abstract
Et farmasøytisk preparat som omfatter minst en omega-3 flerumettet fettsyre i fri form eller som et farmakologisk derivat er innesluttet i en myk gelatinkapsel, hvor kapselen omfatter gelatin ekstrahert ved en ekstraksjonsprosess som omfatter syreforbehandling av en kollagenkilde. En fordel ved foreliggende oppfinnelse sammenlignet med en myk gelatinkapsel som inneholder den samme formuleringen, men som omfatter gelatin ved en ekstraksjonsprosess som omfatter alkalisk forbehandling av kollagenkilden, er at den oppnådd ved foreliggende oppfinnelse ikke hardner vesentlig over tid og følgelig har lenger holdbarhet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0403247A GB0403247D0 (en) | 2004-02-13 | 2004-02-13 | A pharmaceutical composition |
PCT/GB2005/000415 WO2005079853A2 (en) | 2004-02-13 | 2005-02-07 | Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20064146L true NO20064146L (no) | 2006-11-10 |
NO341821B1 NO341821B1 (no) | 2018-01-29 |
Family
ID=32011882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064146A NO341821B1 (no) | 2004-02-13 | 2006-09-13 | Myk gelatinkapsel inneholdende omega-3 flerumettet fettsyre |
Country Status (23)
Country | Link |
---|---|
US (6) | US7960370B2 (no) |
EP (1) | EP1755565B2 (no) |
JP (3) | JP5435842B2 (no) |
KR (1) | KR101198458B1 (no) |
CN (1) | CN1929824B (no) |
AR (1) | AR047799A1 (no) |
AT (1) | ATE457720T2 (no) |
AU (1) | AU2005215198B2 (no) |
BR (1) | BRPI0507473B8 (no) |
CA (1) | CA2555064C (no) |
CY (1) | CY1110030T1 (no) |
DE (1) | DE602005019402D1 (no) |
DK (1) | DK1755565T4 (no) |
ES (1) | ES2344208T5 (no) |
GB (1) | GB0403247D0 (no) |
IL (1) | IL177462A (no) |
MX (1) | MXPA06008352A (no) |
NO (1) | NO341821B1 (no) |
PL (1) | PL1755565T5 (no) |
PT (1) | PT1755565E (no) |
SI (1) | SI1755565T2 (no) |
WO (1) | WO2005079853A2 (no) |
ZA (1) | ZA200606229B (no) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552917A (zh) | 2003-08-13 | 2012-07-11 | 比奥孔有限公司 | 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂 |
GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
AU2008272135B2 (en) * | 2007-06-29 | 2013-10-31 | Takeda Pharmaceutical Company Limited | Seamless capsule |
US9763989B2 (en) | 2007-08-03 | 2017-09-19 | Shaklee Corporation | Nutritional supplement system |
WO2009035496A1 (en) | 2007-08-03 | 2009-03-19 | Shaklee Corporation | Nutritional dosage unit |
US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
US20100130608A1 (en) * | 2008-10-01 | 2010-05-27 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
WO2010103402A1 (en) * | 2009-03-09 | 2010-09-16 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof |
US8207363B2 (en) | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
WO2011048493A1 (en) * | 2009-10-23 | 2011-04-28 | Pronova Biopharma Norge As | Coated capsules and tablets of a fatty acid oil mixture |
JP2011136927A (ja) * | 2009-12-28 | 2011-07-14 | Pfizer Inc | ゼラチンカプセル及びカプセル皮膜成形用ゼラチン組成物 |
KR20150013667A (ko) | 2010-01-19 | 2015-02-05 | 디에스엠 아이피 어셋츠 비.브이. | 에이코사펜타엔산 생산 미생물, 지방산 조성물 및 이의 제조방법 및 용도 |
KR20130139896A (ko) * | 2010-09-08 | 2013-12-23 | 프로노바 바이오파마 너지 에이에스 | 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물 |
WO2012037311A1 (en) | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil and uses thereof |
WO2012037328A2 (en) * | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
KR102149068B1 (ko) | 2011-07-21 | 2020-08-31 | 디에스엠 아이피 어셋츠 비.브이. | 지방산 조성물 |
WO2013040507A1 (en) * | 2011-09-15 | 2013-03-21 | Omthera Pharmaceuticals, Inc. | Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800563B1 (en) * | 2012-01-06 | 2018-07-11 | Omthera Pharmaceuticals Inc. | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
EP2833740B1 (en) * | 2012-04-04 | 2016-09-14 | Pronova BioPharma Norge AS | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
JP2015512945A (ja) * | 2012-04-13 | 2015-04-30 | バナー ファーマキャップス,インコーポレイティド | 錠剤と液体または半固体の充填剤とを含む軟質弾性カプセル、ならびにそれらの製造方法 |
HUE036187T2 (hu) | 2012-04-30 | 2018-06-28 | Tillotts Pharma Ag | Késleltetett leadású gyógyszerkészítmény |
AR095182A1 (es) | 2012-05-07 | 2015-09-30 | Omthera Pharmaceuticals Inc | Composiciones de estatinas y ácidos grasos omega-3 |
EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT |
GB201216385D0 (en) | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
UA117260C2 (uk) | 2013-10-29 | 2018-07-10 | Тиллоттс Фарма АГ | Лікарський препарат з відстроченим вивільненням |
US9895332B2 (en) | 2013-10-30 | 2018-02-20 | Patheon Softgels, Inc. | Enteric soft capsules comprising polyunsaturated fatty acids |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
MX2016016830A (es) | 2014-06-18 | 2017-07-07 | Thetis Pharmaceuticals Llc | Complejos de aminoacidos minerales de agentes activos. |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
CA2950444C (en) * | 2014-06-26 | 2021-01-12 | Banner Life Sciences Llc | Enhanced bioavailability of polyunsaturated fatty acids |
EP3185869A1 (en) * | 2014-08-28 | 2017-07-05 | Dezima Pharma B.V. | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS |
CN105434393B (zh) * | 2014-09-25 | 2019-07-09 | 四川国为制药有限公司 | 一种包含高含量ω-3多不饱和脂肪酸的软胶囊药物组合物 |
MA41611A (fr) * | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
KR102437682B1 (ko) | 2016-06-03 | 2022-08-29 | 테티스 파마수티컬스 엘엘씨 | 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법 |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
GB2571749A (en) * | 2018-03-07 | 2019-09-11 | Anabio Tech Limited | A method inducing satiety in a mammal |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
CN109567180B (zh) * | 2019-02-02 | 2022-03-22 | 北京振东光明药物研究院有限公司 | 一种可用于女性经、孕、产、乳期的营养品及其制备方法 |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2868661A (en) * | 1954-08-04 | 1959-01-13 | Wilson & Co Inc | Sensitizing photographic gelatin |
US2870062A (en) * | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
US2888661A (en) | 1956-12-13 | 1959-05-26 | Radio Frequency Lab | Adapter for magnet charger |
US3108995A (en) | 1957-03-01 | 1963-10-29 | Charles B Knox Gelatine Co Inc | Method of modifying type a gelatin and product thereof |
AU527784B2 (en) | 1978-05-26 | 1983-03-24 | Bang, Hans Olaf Dr. | Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid |
JPS55154533A (en) | 1979-05-18 | 1980-12-02 | Kawasaki Steel Corp | Stacking method for starting material such as ore |
JPS5735512A (en) | 1980-06-27 | 1982-02-26 | Nippon Oil & Fats Co Ltd | Preventive and remedy for thrombosis |
JPS609011B2 (ja) | 1981-10-09 | 1985-03-07 | 富士カプセル株式会社 | 軟カプセル皮膜 |
EP0100052A1 (en) | 1982-07-19 | 1984-02-08 | Syntex (U.S.A.) Inc. | PGE type compositions encapsulated by acid isolated gelatin |
JPS5939834A (ja) * | 1982-08-31 | 1984-03-05 | Morishita Jintan Kk | 製剤用皮膜組成物 |
DE3438291A1 (de) * | 1984-10-19 | 1986-04-24 | Röhm GmbH, 6100 Darmstadt | Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln |
DE3678643D1 (de) | 1985-08-16 | 1991-05-16 | Procter & Gamble | Partikel mit konstanter wirkstofffreisetzung. |
SE8505569D0 (sv) | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
IL77186A0 (en) | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
JPS62201823A (ja) | 1986-02-28 | 1987-09-05 | Freunt Ind Co Ltd | 腸内有用細菌含有物およびその製造方法 |
DE3615710A1 (de) * | 1986-05-09 | 1987-11-26 | Hoechst Ag | Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
GB8719988D0 (en) | 1987-08-25 | 1987-09-30 | Efamol Ltd | Chemical compounds |
ES2040847T3 (es) | 1987-04-27 | 1996-07-16 | Efamol Holdings | Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio. |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
JPH0774150B2 (ja) | 1987-07-31 | 1995-08-09 | 新田ゼラチン株式会社 | 肝油用ソフトカプセル |
US4895725A (en) | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
DE3734147C2 (de) | 1987-10-09 | 1998-10-29 | Braun Melsungen Ag | Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
PT93637A (pt) | 1989-04-20 | 1990-11-20 | Procter & Gamble | Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal |
US5292522A (en) * | 1989-06-20 | 1994-03-08 | Rohm Gmbh | Aqueous film coating agent for solid medicaments |
JP2836206B2 (ja) | 1990-07-02 | 1998-12-14 | 味の素株式会社 | 炎症性腸疾患用油脂組成物 |
GB2253346A (en) | 1991-02-22 | 1992-09-09 | John Rhodes | Delayed release oral dosage forms for treatment of intestinal disorders |
US5843482A (en) * | 1990-07-20 | 1998-12-01 | Tillotts Pharma Ag | Products and processes for the treatment of the alimentary canal |
ES2107663T3 (es) | 1992-04-28 | 1997-12-01 | Fresenius Ag | Empleo de una emulsion que contiene acidos grasos omega-3 en la fabricacion de un medicamento a administrar por via parenteral para el tratamiento de las enfermedades inflamatorias. |
JP3895782B2 (ja) | 1992-10-26 | 2007-03-22 | 生化学工業株式会社 | コンドロイチナーゼ組成物およびそれを含有する注射用製剤 |
US5496718A (en) | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
ATE173616T1 (de) * | 1992-11-30 | 1998-12-15 | Pfizer | Verabreichungsvorrichtungen mit gestützten flüssigen membranen |
JPH0741421A (ja) | 1993-05-28 | 1995-02-10 | Suntory Ltd | ロイコトリエンb4 (ltb4 )による医学的症状の予防及び改善剤 |
DK66493D0 (da) | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
DE4422938A1 (de) | 1993-06-30 | 1995-01-12 | Siegfried Ag Pharma | Neue Weichgelatinekapseln |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
JPH11106333A (ja) | 1997-09-30 | 1999-04-20 | Kuraray Co Ltd | 脂溶性ビタミンおよび/またはカロチノイドを含有する粉末の製造法 |
DE19830375A1 (de) | 1998-07-08 | 2000-01-13 | K D Pharma Bexbach Gmbh | Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen |
CA2386277A1 (en) * | 1999-10-01 | 2001-04-12 | Natco Pharma Limited | An improved pharmaceutical composition and a process for its preparation |
US6555316B1 (en) * | 1999-10-12 | 2003-04-29 | Genset S.A. | Schizophrenia associated gene, proteins and biallelic markers |
MXPA02004666A (es) | 1999-11-12 | 2003-06-24 | Fibrogen Inc | Gelatinas recombinantes. |
JP2001335481A (ja) | 2000-03-22 | 2001-12-04 | Eisai Co Ltd | 高濃度ビタミンe含有ソフトカプセル |
ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
US20030161872A1 (en) * | 2002-01-04 | 2003-08-28 | Gan-Lin Chen | Capsule for holding liquid-containing compositions and method for making the same |
US6663900B2 (en) * | 2002-02-01 | 2003-12-16 | Kemin Foods, Lc | Microcapsules having high carotenoid content |
ITMI20020269A1 (it) | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
DE10214002A1 (de) | 2002-03-27 | 2003-10-09 | Roehm Gmbh | Pharmazeutische Formulierung für den Wirkstoff Budesonid |
ITMI20020731A1 (it) | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3 |
US6974592B2 (en) * | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
GB2388776B (en) | 2002-05-21 | 2004-08-25 | Croda Int Plc | Succinylated fish gelatin for use as a blood plasma expander |
EP1549299B1 (en) | 2002-06-05 | 2014-08-20 | IVAX Pharmaceuticals s.r.o. | Reduction of gelatin cross-linking |
BRPI0409585A (pt) * | 2003-04-17 | 2006-04-18 | Boehringer Ingelheim Int | suplemento multivitamìnico e mineral para mulheres grávidas |
GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
GB0413729D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
-
2004
- 2004-02-13 GB GB0403247A patent/GB0403247D0/en not_active Ceased
-
2005
- 2005-02-07 DE DE200560019402 patent/DE602005019402D1/de active Active
- 2005-02-07 CA CA2555064A patent/CA2555064C/en not_active Expired - Fee Related
- 2005-02-07 AU AU2005215198A patent/AU2005215198B2/en not_active Ceased
- 2005-02-07 SI SI200530998T patent/SI1755565T2/en unknown
- 2005-02-07 PL PL05702139T patent/PL1755565T5/pl unknown
- 2005-02-07 EP EP05702139.6A patent/EP1755565B2/en active Active
- 2005-02-07 JP JP2006552677A patent/JP5435842B2/ja not_active Expired - Fee Related
- 2005-02-07 WO PCT/GB2005/000415 patent/WO2005079853A2/en active Application Filing
- 2005-02-07 ES ES05702139.6T patent/ES2344208T5/es active Active
- 2005-02-07 BR BRPI0507473A patent/BRPI0507473B8/pt not_active IP Right Cessation
- 2005-02-07 PT PT05702139T patent/PT1755565E/pt unknown
- 2005-02-07 US US10/587,201 patent/US7960370B2/en not_active Expired - Fee Related
- 2005-02-07 MX MXPA06008352A patent/MXPA06008352A/es active IP Right Grant
- 2005-02-07 ZA ZA200606229A patent/ZA200606229B/xx unknown
- 2005-02-07 AT AT05702139T patent/ATE457720T2/de active
- 2005-02-07 CN CN2005800046998A patent/CN1929824B/zh not_active Expired - Fee Related
- 2005-02-07 DK DK05702139.6T patent/DK1755565T4/en active
- 2005-02-07 KR KR20067018700A patent/KR101198458B1/ko active IP Right Grant
- 2005-02-11 AR ARP050100509 patent/AR047799A1/es not_active Application Discontinuation
-
2006
- 2006-08-13 IL IL177462A patent/IL177462A/en active IP Right Grant
- 2006-09-13 NO NO20064146A patent/NO341821B1/no not_active IP Right Cessation
-
2010
- 2010-05-14 CY CY101100420T patent/CY1110030T1/el unknown
-
2011
- 2011-01-05 US US12/984,994 patent/US8383678B2/en active Active
-
2012
- 2012-03-16 JP JP2012059540A patent/JP2012149073A/ja active Pending
-
2013
- 2013-01-04 US US13/734,643 patent/US9012501B2/en not_active Expired - Fee Related
-
2014
- 2014-03-24 JP JP2014059433A patent/JP2014139216A/ja active Pending
- 2014-04-22 US US14/258,523 patent/US9132112B2/en not_active Expired - Fee Related
-
2015
- 2015-04-29 US US14/699,719 patent/US20150238430A1/en not_active Abandoned
-
2016
- 2016-11-14 US US15/350,238 patent/US20170056354A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064146L (no) | En farmasoytisk sammensetning | |
CY1124741T1 (el) | Μεθοδος ενος δοχειου για την παρασκευη ρακεμικης νικοτινης με αντιδραση νικοτινικου αιθυλεστερα με ν-βινυλοπυρρολιδονη παρουσια αιθοξειδιου του νατριου η αιθοξειδιου του καλιου η μιγματων αυτων | |
PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
CL2019000586A1 (es) | Composiciones de toxinas clostridiales no proteicas. | |
BRPI0805072B8 (pt) | Composições organizadas compreendendo betaína | |
WO2019051136A8 (en) | DYNAMIC SCRIPT FOR TELEAGENTS | |
DK2211924T3 (da) | Tværbunden hyaluronsyre og collagen og anvendelser deraf | |
AR072058A1 (es) | Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas | |
CL2011000090A1 (es) | Compuestos derivados de ácido grasos sustituidos interrumpido por un grupo azufrado; composicion farmaceutica alimentaria; metodo de preparacion de estos; y su uso en el tratamiento de enfermedades metabólicas, cardiovasculares,entre otras. | |
BR112019024637A2 (pt) | Método para produzir células progenitoras renais, célula progenitora renal, organoide renal, composição farmacêutica, e, agente terapêutico para uma doença renal. | |
BRPI0712205A2 (pt) | Microorganismo, geneticamente modificado e métodos para produção melhorada de ácidos graxos, alcoís graxos, ésteres e cera de ácidos graxos usados em composições biocombustíveis, método para se obter um derivado de ácido graxo, composições biocombustíveis e biocombustiveis | |
BR112015019997A2 (pt) | Métodos de sacarificar e fermentar um material celulósico | |
BR112018013104B8 (pt) | Composição e método para crescimento de cabelos ou pelos | |
BRPI1014472A8 (pt) | Método para produzir um derivado de ácido graxo, microrganismo engenheirado geneticamente, derivado de ácido graxo e composição de biocombustível | |
BRPI0519561A2 (pt) | composiÇço farmacÊutica de hormânio da tireàide, embalagem farmacÊutica, e, mÉtodo de acondicionamento de uma composiÇço farmacÊutica de hormânio da tireàide | |
PE20050923A1 (es) | Composicion solida que comprende un sensibilizador de insulina, un secretagogo de insulina y un ester de acidos grasos | |
DE602006002497D1 (de) | Silikonmemulsion, verfahren zu ihrer herstellung und kosmetischer bestandteil | |
ES2549152T1 (es) | Carragenano modificado mediante un procedimiento de intercambio iónico | |
MX2020003981A (es) | Procesos para reducir acido lactico en un sistema de fermentacion de biocombustible. | |
BR112016009619A2 (pt) | métodos para sacarificar um material celulósico e para produzir um produto de fermentação a partir de material celulósico | |
MX2021003219A (es) | Biomaterial que comprende celulas germinales derivadas de tejido adiposo y gelatina y metodo para producir el mismo. | |
MX2021000766A (es) | Esteres de acido carboxilico a,a-disustituidos para usar como sustancias quimicas aromaticas. | |
CL2009001183A1 (es) | Formulación farmacéutica sólida que comprende a) cilostazol, b) 10 a 90% de un almidón pregelatinizado c) uno o más tipos de ingredientes entéricos, y d) un ácido orgánico. | |
CO2021000418A2 (es) | Composiciones de ácidos grasos poliinsaturados enriquecidos con ala | |
PE20221272A1 (es) | Agente supresor del sabor desagradable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: CHRYSALIS PHARMA AG, CH |
|
MM1K | Lapsed by not paying the annual fees |